Rewiring ERBB3 and ERK signaling confers resistance to FGFR1 inhibition in gastrointestinal cancer harbored an ERBB3-E928G mutation

Saved in:
Bibliographic Details
Published inProtein & cell Vol. 11; no. 12; pp. 915 - 920
Main Authors Yang, Xiang, Wang, Hongxiao, Xie, Enjun, Tang, Biyao, Mu, Qingdian, Song, Zijun, Chen, Junyi, Wang, Fudi, Min, Junxia
Format Journal Article
LanguageEnglish
Published Beijing Higher Education Press 01.12.2020
Springer Nature B.V
Oxford University Press
Subjects
Amino Acid Substitution
Antineoplastic Agents - pharmacology
Biochemistry
Biomedical and Life Sciences
Cell Biology
Cell Line, Tumor
Developmental Biology
Drug Resistance, Neoplasm - drug effects
Drug Resistance, Neoplasm - genetics
ErbB-3 protein
Extracellular signal-regulated kinase
Fibroblast growth factor receptor 1
Gastrointestinal Neoplasms - genetics
Gastrointestinal Neoplasms - metabolism
Gastrointestinal Neoplasms - pathology
Human Genetics
Humans
Letter
Life Sciences
MAP Kinase Signaling System - drug effects
MAP Kinase Signaling System - genetics
Mutation, Missense
Protein Science
Receptor, ErbB-3 - genetics
Receptor, ErbB-3 - metabolism
Receptor, Fibroblast Growth Factor, Type 1 - antagonists & inhibitors
Receptor, Fibroblast Growth Factor, Type 1 - genetics
Receptor, Fibroblast Growth Factor, Type 1 - metabolism
Stem Cells
Online AccessGet full text

Cover

More Information
ISSN:1674-800X
1674-8018
DOI:10.1007/s13238-020-00749-z